Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV

Clinical Pharmacokinetics

Volumn 54, Issue 6, 2015, Pages 639-650

  Rajoli, Rajith K R ^a   Back, David J ^a   Rannard, Steve ^a   Freel Meyers, Caren L ^b   Flexner, Charles ^b   Owen, Andrew ^a   Siccardi, Marco ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LONG ACTING DRUG; RALTEGRAVIR; RILPIVIRINE; TENOFOVIR; TENOFOVIR DISOPROXIL; NANOMATERIAL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CACO 2 CELL LINE; CAPILLARY; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; ELIMINATION HALF-LIFE; FIRST PASS EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYDROGEN BOND; IN VITRO STUDY; INFECTION CONTROL; INHIBITORY CONCENTRATION; INTESTINE ABSORPTION; INTRINSIC CLEARANCE; LIVER CLEARANCE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; NANOFORMULATION; NANOTECHNOLOGY; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; STEADY STATE; SYSTEMIC CIRCULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION PROCESS; VIRTUAL REALITY; VIRUS REPLICATION; VOLUME OF DISTRIBUTION; ADOLESCENT; ALGORITHM; BIOLOGICAL MODEL; BLOOD; CHEMISTRY; COMPUTER SIMULATION; FEMALE; HIV INFECTIONS; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; NANOMEDICINE; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; ALGORITHMS; ANTI-HIV AGENTS; COMPUTER SIMULATION; FEMALE; HIV INFECTIONS; HUMANS; INJECTIONS, INTRAMUSCULAR; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NANOMEDICINE; NANOSTRUCTURES; YOUNG ADULT;

EID: 84930086174     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0227-1     Document Type: Article

References (53)

1. UNAIDS. AIDS by the numbers 2013. http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2013/JC2571_AIDS_by_the_numbers_en.pdf. Accessed 20 Oct 2014.
2. Palleja S, Ogden R, Hamy F, Vidal V, Klimkait T, Martin D, et al. In vitro anti-HIV efficacy of the chemokine receptor 5 (CCR5) antagonist TBR-652 in combination with four other classes of antiretroviral agents [poster no. 416]. 49th ICAAC; 12–15 Sep 2009; San Francisco.
3. Okwundu CI, Uthman OA, Okoromah CAN. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev. 2012;(7):CD007189. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007189.pub3/abstract. Accessed 4 Dec 2014.
4. Spreen WR, Margolis DA, Pottage JCJ. Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS. 2013;8(6):565–71. doi:10.1097/COH.0000000000000002.
5. Boffito M, Jackson A, Owen A, Becker S. New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents. Drugs. 2014;74(1):7–13. doi:10.1007/s40265-013-0163-7.
6. van’t Klooster G, Hoeben E, Borghys H, Looszova A, Bouche M-P, van Velsen F, et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother. 2010;54(5):2042–50. doi:10.1128/aac.01529-09.
7. Williams J, Sayles HR, Meza JL, Sayre P, Sandkovsky U, Gendelman HE, et al. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine (Lond). 2013;8(11):1807–13. doi:10.2217/nnm.12.214.
8. Siccardi M, Rajoli RKR, Curley P, Olagunju A, Moss D, Owen A. Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. Future Virol. 2013;8(9):871–90. doi:10.2217/fvl.13.67.
9. Tegenge M, Mitkus R. A physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccines. J Pharmacokinet Pharmacodyn. 2013;40(5):545–56. doi:10.1007/s10928-013-9328-y.
10. McDonald TO, Giardiello M, Martin P, Siccardi M, Liptrott NJ, Smith D, et al. Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation. Adv Healthc Mater. 2014;3(3):400–11. doi:10.1002/adhm.201300280.
11. Siccardi M, Almond L, Schipani A, Csajka C, Marzolini C, Wyen C, et al. Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro–in vivo extrapolation model. Clin Pharmacol Ther. 2012;92(4):494–502. doi:10.1038/clpt.2012.61.
12. de Roche M, Siccardi M, Stoeckle M, Livio F, Back D, Battegay M, et al. Efavirenz in an obese HIV-infected patient––a report and an in vitro–in vivo extrapolation model indicate risk of underdosing. Antivir Ther. 2012;17(7):1381–4. doi:10.3851/imp2107.
13. Hyland R, Dickins M, Collins C, Jones H, Jones B. Maraviroc: in vitro assessment of drug–drug interaction potential. Br J Clin Pharmacol. 2008;66(4):498–507. doi:10.1111/j.1365-2125.2008.03198.x.
14. Bosgra S, Eijkeren JV, Bos P, Zeilmaker M, Slob W. An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry. Crit Rev Toxicol. 2012;42(9):751–67. doi:10.3109/10408444.2012.709225.
15. Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm. 1999;186(2):119–25. doi:10.1016/S0378-5173(99)00147-7.
16. Siccardi M, Olagunju A, Seden K, Ebrahimjee F, Rannard S, Back D, et al. Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. In Silico Pharmacol. 2013;1:4. doi:10.1186/2193-9616-1-4.
17. Gertz M, Harrison A, Houston JB, Galetin A. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos. 2010;38(7):1147–58. doi:10.1124/dmd.110.032649.
18. Barter ZE, Chowdry JE, Harlow JR, Snawder JE, Lipscomb JC, Rostami-Hodjegan A. Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metab Dispos. 2008;36(12):2405–9. doi:10.1124/dmd.108.021311.
19. Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci. 2002;91(1):129–56. doi:10.1002/jps.10005.
20. Peters S. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet. 2008;47(4):261–75. doi:10.2165/00003088-200847040-00004.
21. GlaxoSmithKline. Summary of product characterisitics–Zinacef. 1979. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/zinacef_30/WC500127791.pdf. Accessed 17 Aug 2014.
22. Duwal S, Schütte C, von Kleist M. Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection. PloS One. 2012;7(7):e40382. doi:10.1371/journal.pone.0040382.
23. Wang LH, Begley J, St Claire RL, Harris J, Wakeford C, Rousseau FS. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retrovir. 2004;20(11):1173–82. doi:10.1089/0889222042544965.
24. Feng J, Ly J, Myrick F, Goodman D, White K, Svarovskaia E, et al. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology. 2009;6(1):1–16. doi:10.1186/1742-4690-6-44.
25. Wilson JE, Martin JL, Borroto-Esoda K, Hopkins S, Painter G, Liotta DC, et al. The 5′-triphosphates of the (−) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine equally inhibit human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1993;37(8):1720–2. doi:10.1128/aac.37.8.1720.
26. Abduljalil K, Cain T, Humphries H, Rostami-Hodjegan A. Deciding on success criteria for predictability of pharmacokinetic parameters from in vitro studies: an analysis based on in vivo observations. Drug Metab Dispos. 2014;. doi:10.1124/dmd.114.058099.
27. Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s). Addendum to Ondqa Biopharmaceutics review. 2011. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202022Orig1s000ClinPharmR.pdf. Accessed 22 Oct 2014.
28. Azijn H, Tirry I, Vingerhoets J, de Béthune M-P, Kraus G, Boven K, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-Resistant HIV-1. Antimicrob Agents Chemother. 2010;54(2):718–27. doi:10.1128/aac.00986-09.
29. Highlights of prescribing information––REYATAZ. Bristol-Myers Squibb Company; 2014. http://packageinserts.bms.com/pi/pi_reyataz.pdf. Accessed 13 Aug 2014.
30. Acosta EP, Limoli KL, Trinh L, Parkin NT, King JR, Weidler JM, et al. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. Antimicrob Agents Chemother. 2012;56(11):5938–45. doi:10.1128/aac.00691-12.
31. Highlights of prescribing information––TIVICAY. Viiv Healthcare; 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204790lbl.pdf. Accessed 11 Oct 2014.
32. Castellino S, Moss L, Wagner D, Borland J, Song I, Chen S, et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor, dolutegravir, in humans. Antimicrob Agents Chemother. 2013;57:3536–46. doi:10.1128/aac.00292-13.
33. Highlights of prescribing information––EMTRIVA. Gilead Sciences; 2013. http://www.gilead.com/~/media/Files/pdfs/medicines/hiv/emtriva/emtriva_pi.pdf. Accessed 12 Oct 2014.
34. Villani P, Regazzi MB, Castelli F, Viale P, Torti C, Seminari E, et al. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Br J Clin Pharmacol. 1999;48(5):712–5. doi:10.1046/j.1365-2125.1999.00071.x.
35. Kakuda TN, Schöller-Gyüre M, Workman C, Arasteh K, Pozniak AL, De Smedt G, et al. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients. Antivir Ther. 2008;13(5):655–61.
36. Fayet Mello A, Buclin T, Franc C, Colombo S, Cruchon S, Guignard N. Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. J Antimicrob Chemother. 2011;66(7):1573–81. doi:10.1093/jac/dkr151.
37. Yilmaz A, Gisslén M, Spudich S, Lee E, Jayewardene A, Aweeka F, et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PloS One. 2009;4(9):e6877. doi:10.1371/journal.pone.0006877.
38. Summary of product characteristics––VIREAD. Gilead Sciences; 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000419/WC500051737.pdf. Accessed 15 Aug 2014.
39. Dolgin E. Long-acting HIV drugs advanced to overcome adherence challenge. Nat Med. 2014;20(4):323–4. doi:10.1038/nm0414-323.
40. Jackson AGA, Else LJ, Mesquita PMM, Egan D, Back DJ, Karolia Z, et al. A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. Clin Pharmacol Ther. 2014;96(3):314–23. doi:10.1038/clpt.2014.118.
41. Martin P, Giardiello M, McDonald TO, Rannard SP, Owen A. Mediation of in vitro cytochrome P450 activity by common pharmaceutical excipients. Mol Pharm. 2013;10(7):2739–48. doi:10.1021/mp400175n.
42. Product information––TIVICAY. ViiV Healthcare Pty Ltd; 2014. http://www.medicines.org.au/files/viptivic.pdf. Accessed 20 Oct 2014.
43. Siccardi M, Marzolini C, Seden K, Almond L, Kirov A, Khoo S, et al. Prediction of drug–drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. Clin Pharmacokinet. 2013;52(7):583–92. doi:10.1007/s40262-013-0056-7.
44. Schöller-Gyüre M, Kakuda T, Raoof A, Smedt G, Hoetelmans RW. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet. 2009;48(9):561–74. doi:10.2165/10895940-000000000-00000.
45. Moss DM, Siccardi M, Back DJ, Owen A. Predicting intestinal absorption of raltegravir using a population-based ADME simulation. J Antimicrob Chemother. 2013;68:1627–34. doi:10.1093/jac/dkt084.
46. Wajima T, Kubota R. Pharmacokinetic/pharmacodynamic modeling and long-term simulation of dolutegravir (DTG, S/GSK1349572) in integrase resistant patients with a simple viral dynamic model [poster]. 20th Population Approach Group in Europe (PAGE); 7–10 Jun 2011; Athens.
47. Valade E, Treluyer J-M, Bouazza N, Ghosn J, Foissac F, Benaboud S, et al. Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients. Antimicrob Agents Chemother. 2014;58(4):2256–61. doi:10.1128/aac.02058-13.
48. Baheti G, Kiser JJ, Havens PL, Fletcher CV. Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. Antimicrob Agents Chemother. 2011;55(11):5294–9. doi:10.1128/aac.05317-11.
49. Colombo S, Buclin T, Cavassini M, Décosterd LA, Telenti A, Biollaz J, et al. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2006;50(11):3801–8. doi:10.1128/aac.00098-06.
50. Laufer R, Paz OG, Di Marco A, Bonelli F, Monteagudo E, Summa V, et al. Quantitative prediction of human clearance guiding the development of raltegravir (MK-0518, Isentress) and related HIV integrase inhibitors. Drug Metabol Dispos. 2009;37(4):873–83. doi:10.1124/dmd.108.023804.
51. Kiser J, Carten M, Aquilante C, Anderson P, Wolfe P, King T, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2007;83(2). doi:10.1038/sj.clpt.6100269.
52. Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metabol Dispos. 2013;41(2):353–61. doi:10.1124/dmd.112.048918.
53. Yanakakis LJ, Bumpus NN. Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos. 2012;40(4):803–14. doi:10.1124/dmd.111.044404.